Drugs / DuoCAR20.19.22-D95
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06879340 | Mar 2025 → Mar 2030 expected | B-cell acute lymphoblastic leukemia | University of Kansas Medical Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DuoCAR20.19.22-D95 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879340 ↗ |
| Modality | Cell therapy | “Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell...” NCT06879340 ↗ |